These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pharmacokinetics of gentamicin in hemodialysis patients: a comparative study between diabetic and non-diabetic patients.
    Author: Al-Homrany MA, Irshaid YM, El Sherif AK, Omar HA.
    Journal: Int Urol Nephrol; 2009; 41(3):663-9. PubMed ID: 18766456.
    Abstract:
    Diabetic nephropathy is one of the leading causes of end-stage renal disease (ESRD). There is some evidence that differences in extracellular fluid volume and capillary permeability do exist between diabetic and non-diabetic patients. This may have an impact on the gentamicin volume of distribution and clearance and thus dosing regimen. The pharmacokinetic parameters of gentamicin [volume of distribution (Vd), clearance (CL), elimination rate constant (K), and half life of elimination (t((1/2)))] were studied before hemodialysis in 20 non-diabetic patients (controls) and 20 diabetic patients, in addition to its hemodialysis clearance.There were no statistically significant differences in Vd, CL, K, and t((1/2)) of gentamicin between the control and diabetic group. Therefore, a composite Vd of 0.25 l/kg and clearance of 0.063 ml/min/kg are suggested for dose calculation for both groups of patients. The mean hemodialysis clearance of gentamicin was higher in the diabetic (87.3 ml/min) than the control group (68.5 ml/min), comparing means by the unpaired t-test (P = 0.018).In conclusion, the same method can be used to calculate the loading dose of gentamicin in ESRD patients between dialysis sessions in both controls and diabetics, whereas, diabetics are expected to receive a higher replacement dose after the end of dialysis.
    [Abstract] [Full Text] [Related] [New Search]